Samsara BioCapital, L.P. (CIK 1699737) reported 6 SEC Form 4 insider transactions across 2 companies over the past 18 months (most recent 2026-05-22). Recent activity: Buy KLRS (244,300 shares), Sell KLRS (66,906 shares), Buy KLRS (14,937 shares), Buy KLRS (4,471 shares), Buy KLRS (479,847 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-22 | Kalaris Therapeutics, Inc. (KLRS) | Insider | Buy | 244,300 | $1.2M |
| 2026-05-22 | Kalaris Therapeutics, Inc. (KLRS) | Insider | Sell | 66,906 | $0 |
| 2026-05-22 | Kalaris Therapeutics, Inc. (KLRS) | Insider | Buy | 14,937 | $0 |
| 2026-05-22 | Kalaris Therapeutics, Inc. (KLRS) | Insider | Buy | 4,471 | $0 |
| 2026-02-17 | Kalaris Therapeutics, Inc. (KLRS) | Insider | Buy | 479,847 | $5.0M |
| 2025-03-17 | Mineralys Therapeutics, Inc. (MLYS) | Insider | Buy | 600,000 | $8.1M |
Source: SEC Form 4 filings · as of 2026-05-22